Key Highlights

  • Novo Nordisk shares were trading roughly flat, down 0.03% near $47.07, stabilizing after last week's sharp selloff.
  • The prior selloff was triggered by the ZEUS trial's failure to show ziltivekimab reduced major adverse cardiovascular events versus placebo.
  • The trial did show ziltivekimab achieved its intended biological effect, reducing free IL-6 and hsCRP inflammation markers, but this did not translate into a cardiovascular benefit.
  • Novo Nordisk said the outcome will not affect its 2026 adjusted operating profit outlook but will result in a non-cash impairment charge in the third quarter.
  • Investors are also watching broader pharma M&A activity, including the AstraZeneca-Bristol Myers merger talks and Novo's competitive positioning in the GLP-1 space against Eli Lilly.

What's Happening With the Stock

Novo Nordisk (NYSE:NVO) shares were trading little changed, down 0.03% near $47.07, with a day range of $46.19 to $47.17 on volume of 9.08 million shares. The stabilization comes after last week's sharp selloff, which sent the stock down as much as 9% to 10% on July 31 following results from the company's ZEUS cardiovascular outcomes trial.

The ZEUS trial, a double-blind, placebo-controlled study enrolling more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, evaluated once-monthly ziltivekimab 15 mg versus placebo for reducing major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. While ziltivekimab demonstrated the expected biological effect, reflected in reductions of free IL-6 and high-sensitivity C-reactive protein, this did not translate into a reduction in cardiovascular event risk, with a hazard ratio of 0.99 versus placebo.

Novo Nordisk executive vice president and chief scientific officer Martin Holst Lange said the study did not achieve the hoped-for benefit but does not change the company's strategic commitment to cardiovascular disease, noting the results will inform ongoing cardiovascular research. Two additional ongoing cardiovascular outcomes trials investigating ziltivekimab, in heart failure and following acute heart attack, are planned to continue and are expected to read out in the first half of 2027.

Financial Impact and Sector Context

The company said the ZEUS outcome will not impact its previously communicated 2026 adjusted operating profit outlook, though it will result in a non-cash impairment charge in the third quarter of 2026. Full trial results are expected to be presented at an upcoming scientific meeting later this year.

Investors are also watching broader pharma merger and acquisition activity, including reported merger talks between AstraZeneca (NYSE:AZN) and Bristol Myers Squibb (NYSE:BMY), as well as continued scrutiny of Novo's competitive positioning in the GLP-1 obesity and diabetes market against rival Eli Lilly (NYSE:LLY). Analyst consensus on the stock remains outperform-leaning, though with a wide target dispersion ranging from DKK200 to DKK454.

Novo Nordisk's market capitalization stood at $209.48 billion intraday, with shares trading at a trailing price-to-earnings ratio of 11.70 and a dividend yield of 3.87%. The stock's 52-week range spans $35.12 to $64.16, reflecting the scale of the decline the stock has experienced over the past year.

Conclusion

Novo Nordisk's stabilization today suggests the market has largely absorbed the disappointment from the ZEUS trial's failure to meet its primary endpoint, with the company reiterating that its overall financial outlook remains intact. With two additional cardiovascular trials for ziltivekimab still to read out in 2027, and broader pharma sector volatility continuing to influence trading, the stock's next major catalyst is likely to come from either those studies or further developments in the competitive GLP-1 landscape.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.